Cullinan Therapeutics Inc (CGEM)

NASDAQ:CGEM

CGEM

Cullinan Management

RESEARCH TOOLSreports

Want to see CGEM full AI Analyst Report?

Cullinan Management (CGEM) Price & Analysis

350 Followers

CGEM Stock Chart & Stats

$15.06

-$0.28(-2.38%)

At close: Jan 08 4:00 PM EST

$15.06

-$0.28(-2.38%)

Day’s Range― - ―

52-Week Range$5.68 - $16.74

Previous CloseN/A

Volume73.34K

Average Volume (3M)936.15K

Market Cap

$1.01B

Enterprise Value$937.67M

Total Cash (Recent Filing)$351.88M

Total Debt (Recent Filing)$2.38M

Price to Earnings (P/E)―

Beta0.81

Next Earnings

Aug 06, 2026

EPS Estimate

-0.81

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.75

Shares Outstanding61,458,046

10 Day Avg. Volume1,103,116

30 Day Avg. Volume936,151

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)1.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.48

Enterprise Value/Market Cap0.93

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-11.87K

Enterprise Value/Ebitda-3.99

Forecast

1Y Price Target

$31.78

Price Target Upside111.01% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-3.06

Revenue Forecast (FY)$19.68M

Bulls Say, Bears Say

Bulls Say

Promising CLN-978 Autoimmune Phase 1 DataRobust early CLN-978 results (B‑cell depletion, favorable safety, early efficacy) materially de‑risk the autoimmune program. Durable over months, positive Phase 1 signals can attract partners, justify further investment, and position the drug as a differentiated, off‑the‑shelf B‑cell therapy if later trials confirm efficacy.

Orphan Drug Designation For CLN-049 (FLT3xCD3)Orphan designation for CLN‑049 provides regulatory incentives (potential priority review, fee waivers, market exclusivity) that strengthen development economics and partner interest. Structurally this reduces regulatory execution risk and can enhance commercial viability for an AML T‑cell engager over the medium term.

Very Low Financial LeverageExtremely low leverage gives the company financial flexibility and lower near‑term solvency risk despite cash burn. This durable strength reduces refinancing pressure, supports continued R&D spending or partnering negotiations, and preserves strategic optionality over the coming months.

Bears Say

High And Worsening Cash BurnOperating cash flow is materially negative and deteriorating, indicating persistent cash consumption to fund R&D. Over 2–6 months this implies continued dependence on external financing or partnerships, raising dilution risk and constraining the firm's ability to self‑fund multiple programs simultaneously.

Essentially No Revenue / Pre-commercial ProfileThe lack of recurring product revenue means the business relies on milestone, licensing, or financing events. This structural absence of revenue leaves operating funding uncertain and makes long‑term sustainability contingent on successful trials, partnerships, or dilutive capital raises.

Declining Equity And Deeply Negative ROEA sharp decline in equity and very negative ROE reflect cumulative losses and erosion of shareholder capital. This durable deterioration weakens the balance sheet buffer, may limit access to non‑dilutive financing, and signals structural shareholder value destruction unless operating performance improves.

Cullinan Management News

Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig

Cullinan Therapeutics (CGEM) announced that the Company will host an in-person Immunology Day event in New York City...

8d ago

CGEM

Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street

Clear Street reiterated a Buy rating and $33 price target on Cullinan Therapeutics (CGEM), saying the firm views...

14d ago

CGEM

Cullinan Therapeutics receives orphan drug designation for CLN-049

Cullinan Therapeutics (CGEM) announced that the FDA has granted orphan drug designation to CLN-049, a novel, investigational FLT3xCD3...

15d ago

CGEM

Cullinan Therapeutics price target raised to $37 from $36 at Wedbush

Wedbush raised the firm’s price target on Cullinan Therapeutics (CGEM) to $37 from $36 and keeps an Outperform...

26d ago

CGEM

Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)

“T cell engagers have the potential to transform outcomes for people living with autoimmune diseases and cancer, and...

27d ago

CGEM

Cullinan jumps after UCB acquires Candid Therapeutics

Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held...

30d ago

CGEM

Cullinan Management Shares Promising Early CLN-978 Autoimmune Data

Cullinan Management ( ($CGEM) ) has shared an announcement. On May 18, 2026, Cullinan Therapeutics reported initial clinical...

15d ago

CGEM

Cullinan Oncology: FDA Acceptance of Zipalertinib NDA and Upcoming CLN-978 Data Underpin Buy Rating and Favorable NPV Outlook

William Blair analyst Matt Phipps has maintained their bullish stance on CGEM stock, giving a Buy rating today....

1M ago

CGEM

Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Cullinan Therapeutics (CGEM) to $30 from $27...

1M ago

CGEM

Cullinan Therapeutics announces U.S. FDA accepted NDA for zipalertinib

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced that the U.S. Food and Drug Administration, FDA, has...

1M ago

CGEM

Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig

Clear Street says that Gilead’s (GILD) up to $2.2B acquisition of Ouro Medicines’ sole asset OM336 underscores the...

2M ago

CGEM

GILD

Cullinan Therapeutics price target raised to $36 from $34 at Wedbush

Wedbush raised the firm’s price target on Cullinan Therapeutics (CGEM) to $36 from $34 and keeps an Outperform...

3M ago

CGEM

Cullinan: Advancing Immunology and Oncology Pipeline Undervalued; Buy Rating on CLN-978 Catalysts and Strong Cash Runway

Analyst Julian Harrison of BTIG maintained a Buy rating on Cullinan Management, with a price target of $38.00....

3M ago

CGEM

Cullinan Management Adopts Reduced SEC Reporting: Lower Compliance Costs, But Potential Hit to Investor Appeal and Liquidity

Cullinan Management, Inc. (CGEM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Cullinan...

3M ago

CGEM

CGEM FAQ

What was Cullinan Therapeutics Inc’s price range in the past 12 months?

Cullinan Therapeutics Inc lowest stock price was $5.68 and its highest was $16.74 in the past 12 months.

What is Cullinan Therapeutics Inc’s market cap?

Cullinan Therapeutics Inc’s market cap is $1.01B.

When is Cullinan Therapeutics Inc’s upcoming earnings report date?

Cullinan Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.

How were Cullinan Therapeutics Inc’s earnings last quarter?

Cullinan Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.836 by $0.086.

Is Cullinan Therapeutics Inc overvalued?

According to Wall Street analysts Cullinan Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cullinan Therapeutics Inc pay dividends?

Cullinan Therapeutics Inc does not currently pay dividends.

What is Cullinan Therapeutics Inc’s EPS estimate?

Cullinan Therapeutics Inc’s EPS estimate is -0.81.

How many shares outstanding does Cullinan Therapeutics Inc have?

Cullinan Therapeutics Inc has 61,458,046 shares outstanding.

What happened to Cullinan Therapeutics Inc’s price movement after its last earnings report?

Cullinan Therapeutics Inc reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.836. Following the earnings report the stock price went down -1.801%.

Which hedge fund is a major shareholder of Cullinan Therapeutics Inc?

Currently, no hedge funds are holding shares in CGEM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cullinan Management Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.45%

Trailing 12-Months

Asset Growth

-30.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cullinan Therapeutics Inc

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Management (CGEM) Earnings & Revenues

Historic Earnings Reports

CGEM Stock 12 Month Forecast

Average Price Target

$31.78

▲(111.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","39":"$39","13.5":"$13.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.77777777777778,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,13.5,22,30.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.21,17.886153846153846,19.562307692307694,21.23846153846154,22.914615384615384,24.590769230769233,26.266923076923078,27.943076923076923,29.619230769230768,31.295384615384616,32.97153846153846,34.64769230769231,36.323846153846155,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.21,17.40752136752137,18.605042735042737,19.802564102564105,21.000085470085473,22.19760683760684,23.395128205128206,24.592649572649574,25.790170940170942,26.98769230769231,28.185213675213678,29.382735042735042,30.58025641025641,{"y":31.77777777777778,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.21,16.80923076923077,17.408461538461538,18.00769230769231,18.606923076923078,19.206153846153846,19.805384615384614,20.404615384615383,21.003846153846155,21.603076923076923,22.20230769230769,22.801538461538463,23.400769230769228,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >